Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial-Reference-Cited by-同舟云学术

Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial

Published:2021-04-21 Issue:590 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Le Lay John E.¹^ORCID,Du Qun²^ORCID,Mehta Minal B.¹^ORCID,Bhagroo Nicholas¹,Hummer B. Timothy³^ORCID,Falloon Judith⁴^ORCID,Carlson Glenn⁵^ORCID,Rosenbaum Anton I.⁶^ORCID,Jin ChaoYu⁷,Kimko Holly⁸^ORCID,Tsai Lan-Feng⁹^ORCID,Novick Steven¹⁰^ORCID,Cook Bill⁴,Han David¹¹^ORCID,Han Chang Yeop¹²,Vaisar Tomas¹²^ORCID,Chait Alan¹²^ORCID,Karathanasis Sotirios K.¹³,Rhodes Christopher J.¹³^ORCID,Hirshberg Boaz⁴^ORCID,Damschroder Melissa M.²^ORCID,Hsia Judith⁴^ORCID,Grimsby Joseph S.¹³^ORCID

Affiliation:

1. Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

2. Biologic Therapeutics, Antibody Discovery and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

3. CVRM Safety, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

4. Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA.

5. Clinical CV, Late Stage Development, CVRM, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD 20878, USA.

6. Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA.

7. Clinical Immunology and Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA 94080, USA.

8. Clinical Pharmacology and DMPK, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

9. CVRM Biometrics, Data Sciences and AI, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

10. Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

11. Parexel International, Glendale, CA 91206, USA.

12. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA 98915, USA.

13. Research and Early Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

Abstract

Neutralization of endothelial lipase with a monoclonal antibody raises functional HDL in both nonhuman primates and in healthy humans.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference56 articles.

1. Genetics of coronary artery disease: discovery, biology and clinical translation

2. Epidemiology: Disease Associations and Modulators of HDL-Related Biomarkers

3. The plasma lecithin:cholesterol acyltransferase reaction

4. Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction

5. HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds;Journal of Medicinal Chemistry;2023-12-19

2. HDL abnormalities in type 2 diabetes: Clinical implications;Atherosclerosis;2023-08

3. Associations between Endothelial Lipase and Apolipoprotein B-Containing Lipoproteins Differ in Healthy Volunteers and Metabolic Syndrome Patients;International Journal of Molecular Sciences;2023-06-26

4. Hepatic Cdkal1 deletion regulates HDL catabolism and promotes reverse cholesterol transport;Atherosclerosis;2023-06

5. The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I;Best Practice & Research Clinical Endocrinology & Metabolism;2023-05